Business
First patient dosed in SCIB1 Phase 2 trial
First patient dosed in SCIB1 Phase 2 trial.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8968S\n Scancell Holdings Plc\n 19 November 2021\n \n \n \n 19 November 2021\n \n Scancell Holdings plc\n (\"Scancell\" or the \"Company\")\n \n First patient dosed in SCIB1 Phase 2 clinical trial\n \n Phase 2 clinical trial of SCIB1 in patients with metastatic melanoma also receiving the checkpoint inhibitor pembrolizumab (Keytruda®)\n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma, who are also eligible for treatment with pembrolizumab.\n \n As a result of the COVID-19 pandemic, screening and recruitment into the study was paused due to the prioritisation of COVID-19 patients in UK hospitals. Patient screening has now been re-initiated in the UK, with Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham as the Chief Investigator. The Nottingham site, along with the Oxford centre, Velindre Hospital and Mount Vernon Hospital are actively screening subjects, with additional centres due to come online in the coming months.\n \n SCIB1 is the lead product from the Company's ImmunoBody® immunotherapy platform, which uses the body's immune system to identify, attack and destroy tumours. This is achieved by delivering a DNA plasmid using Ichor's TriGrid® 2.0 electroporation delivery device to enhance the uptake and presentation of cancer antigens to harness high avidity T cell responses. In a Phase 1/2 clinical trial, survival following SCIB1 monotherapy was superior to historical survival rates, with 14 of 16 resected patients surviving for more than five years. Although pembrolizumab is an approved therapy for advanced melanoma, response to treatment is limited to only a subset of patients (circa 30%). The Phase 2 study is therefore designed to assess whether the addition of SCIB1 treatment to pembrolizumab will result in an improvement in pat...